Investment in CuraVac
Investors in CuraVac, a privately held company, invest because they share the belief—held by all our existing shareholders—that our therapeutic developments can deliver a genuine breakthrough for patients while also being financially rewarding.
Find out where we stand
CuraVac is preparing a crowdfunding campaign. Explore the project, our clinical progress and the next steps.
A major market, still awaiting a cure.
Autoimmune diseases affect a substantial share of the population, yet current care relies on maintenance therapies rather than treatments that deliver lasting remission.
5 to 8%
of the world's population suffers from an autoimmune disease, totalling 400,000 people
0
myasthenia gravis patients (EU, US, Japan) over 5 years, in need of treatment.
0
curative treatment options on the market for myasthenia gravis today.
Platform-addressable market: estimated cases by region
0
Graves' disease
0
Hashimoto's disease
0
Type 1 diabetes
0
Multiple sclerosis
0
Systemic lupus
0
Myasthenia gravis
Opportunity
Market size & potential
Myasthenia gravis remains an unmet medical and economic need — and is the gateway to a platform applicable to many autoimmune diseases.
~$30B
Projected global market value of MG-TAT over 10 years.
~$11.5M
Canine veterinary market, reachable within ~2 years at a fraction of the cost, while accelerating development for humans.
$250–650K
Yearly cost of current biologic treatment per patient.
3
Number of maintenance therapies generating more than $1B yearly, without lasting improvement.
Each year, nearly 200,000 people (prevalence) and 3,000 dogs (incidence) are treated for myasthenia gravis in Europe, North America and Japan — a figure potentially underestimated 3-fold on the canine side.
A de-risked investment
Demonstrated clinical safety, regulatory exclusivity, animal validation and a leading team.
Successful Phase 1b
UZA Antwerp, 2018: excellent tolerability profile and signs of efficacy. Warrants an efficacy Phase 2 with CV-MG02.
EMA & FDA
Orphan drug (EU 2009, US 2011): exclusivity and incentives.
75 %
remission in dogs treated with 3 doses of CV-MG01
MYASTERIX
European FP7 consortium, EC grant of €6M
An experienced team
including a scientific advisory board and experts in development, manufacturing, business, IP, medical, regulatory fields and veterinary care
Agile company: minimal infrastructure, reduced fixed costs, network of experts and subcontractors. Development risk is reduced to the benefit of both investors and patients.
Use of proceeds
More than €18 million raised to date led to the successful Phase 1b results. This new funding round will finance the Phase 2 efficacy clinical trial of CV-MG02, a more potent formulation of the Targeted Active Therapy for MG.
- Preparation and execution of Phase 2 (CV‑MG02) clinical trial.
- GMP manufacturing and stability testing.
- Expansion of the platform to other autoimmune diseases beyond myasthenia gravis.
Funding sources to date
- 75 % Grants
- 20 % Investments
- 5 % Donations
One platform, one lever
The success of the first targeted active therapy in MG validates a complementary-peptide platform applicable to many autoimmune diseases. A single clinical success opens multiple markets.
Discover the full pipelineLet's talk
If you share our goals and our hopes, we invite you to contact us to discuss the project and the terms of participation in person.
Prefer to support us another way? Donate.